Houston, Texas — A new study published in Neurology has found that older adults who receive the high-dose influenza vaccine are nearly 55% less likely to develop Alzheimer’s disease compared to those who get the standard-dose shot — a finding that carries direct implications for nursing homes and long-term care facilities across the country.
Researchers at McGovern Medical School at UTHealth Houston analyzed health data from roughly 165,000 adults aged 65 and older who received either the high-dose or standard-dose flu vaccine. The difference in outcomes was striking. While earlier work by the same team had found the standard-dose flu vaccine linked to a 40% reduced risk of Alzheimer’s, the high-dose version pushed that figure even further.
“Enhanced flu vaccines confer greater protection against influenza infection, thereby decreasing risk of severe illness and the associated systemic inflammation that can promote neuroinflammation and neurodegeneration,” the study authors wrote.
Why it matters for long-term care
Alzheimer’s disease is already the most common reason people enter skilled nursing facilities, and nursing homes have long struggled to keep vaccination rates high among both residents and staff. The new findings give facilities a sharper clinical reason to push for the high-dose vaccine specifically — not just any flu shot.
The CDC already recommends the high-dose flu vaccine for all adults 65 and older. It contains four times the antigen of standard-dose vaccines, which generates a stronger immune response in older adults whose immune systems are naturally less robust.
Industry reports have shown that nursing homes tend to outperform assisted living facilities on vaccination program participation, but the new research may intensify pressure to document specifically which vaccine formulation residents are receiving — not just whether they got vaccinated at all.
The inflammation connection
The leading explanation for the vaccine-Alzheimer’s link centers on inflammation. Researchers believe that flu infections trigger systemic inflammation that can cross into the brain and accelerate the neurodegeneration associated with Alzheimer’s. By producing a stronger immune response, the high-dose vaccine may reduce the severity and duration of infections — and with it, the neuroinflammation that follows.
Both men and women showed a reduced Alzheimer’s risk after receiving the high-dose vaccine. But the protective effect appeared to last longer and be more consistent in women, according to the study.
Eric Topol, MD, professor and executive vice president at Scripps Research, noted that the evidence isn’t as strong as what’s been seen with the shingles vaccine and dementia, but said if the effect is real, it likely works by stimulating the immune system in adults who are prone to age-related immune decline.
Limitations and what comes next
The study’s authors acknowledge its limitations. It’s observational, not a randomized trial, which means healthy-user bias could play a role — people who seek out the higher-dose vaccine may simply be more health-conscious overall. The study also relied on claims data, which can misclassify diagnoses, and lacked information on socioeconomic status and mortality.
Still, the researchers call for further study to better understand how vaccine dose affects immune response, long-term cognitive outcomes, and whether vaccination can slow Alzheimer’s progression in people already showing symptoms.
For nursing homes, the takeaway is straightforward: if staff are already administering flu vaccines each fall — and the data show most are — it’s worth confirming that residents are getting the high-dose formulation. The protection it may offer against Alzheimer’s is one more reason to make sure they do.
